
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed is a promising clinical-stage biotechnology company with a strong focus on developing treatments for age-related neurologic disorders. Positive data from preclinical and clinical trials, indicating the potential of their product candidate Neflamapimod to improve synaptic dysfunction, supports the outlook for the company. Upcoming catalysts, such as additional data presentations and the initiation of a Phase 3 trial, could further solidify the company's position and potential for success in the market. However, there are potential risks involved, such as clinical/regulatory and partnership/financial risks, that investors should keep in mind as the company advances towards pivotal development.
Bears say
CervoMed is facing potential setbacks in their development of Neflamapimod as their pivotal trial for DLB may not complete enrollment until the end of 2027, with top-line data release in 2H28. Their current valuation and price target of $25 is based on a discounted cash flow methodology using a 12% discount rate and a 3% terminal rate. However, there are various risks that could impact their success, such as delays in trial initiation or failure to secure regulatory approval. These factors contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares